A new study of 1,001 women with ovarian cancer found that 14% of them carried a BRCA1 or BRCA2 mutation. However, 44% of those women did not have a family history of breast or ovarian cancer. The BRCA mutations can not only help evaluate risk of developing ovarian cancer, but may direct treatment and can be prognostic – women with a mutation lived longer than those who did not have one.
Read the abstract here
A research team, led by Dr. Ugo Cavallaro and supported by OCRA’s 2019 Collaborative Research Development Grant, made progress toward improving immunotherapies for ovarian cancer. Dr. Frances R. Balkwill, a … Continued
Leaders in the patient advocacy space came together for a wide-ranging study on the often-overlooked challenges faced by caregivers of cancer patients, with Tracy Moore, LCSW, who serves as Ovarian … Continued
A study published in Nature Cancer details how OCRA-funded research has dramatically expanded the impact of DNA and RNA data in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia, … Continued
Get email updates about research news, action alerts, and ways to join the fight.
